TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02921776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aim 1 - VidaTalk - post-extubation
Description: Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aim 2 - VidaTalk - intubated
Description: Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aim 3 - VidaTalk tablet app
Description: Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Aim 3 - attention-control with non-VidaTalk tablet
Description: Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
Study: NCT05373420

Intervention type: OTHER
Intervention: Education level
Description: Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.

Intervention type: OTHER
Intervention: Household net income
Description: Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.

Intervention type: OTHER
Intervention: Gender
Description: Male or female. This variable is obtained from the Belgian national registry.
Study: NCT03294798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2b fusion protein
Description: In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: In comparator group, each subject will recieve 180mcg once per week.
Study: NCT04436042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHand Device
Description: These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
Study: NCT01333709

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical proctectomy with total mesorectal excision
Description: The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
Study: NCT02974673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ejaculatory test
Description: Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
Study: NCT01333709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical proctectomy with total mesorectal excision
Description: The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
Study: NCT04235920

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment (MoCA)
Description: This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment (MoCA)
Description: This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
Study: NCT04434872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Fecal microbiota transplantation through colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Fecal microbiota transplantation through colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: Fecal microbiota transplantation through gastroscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastroscopy
Description: Fecal microbiota transplantation through gastroscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enema
Description: Fecal microbiota transplantation through enema

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Enema
Description: Fecal microbiota transplantation through enema
Study: NCT03556332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
Study: NCT00787176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A Intravenous bolus of 1000 ml lactated ringers solution
Description: An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate
Description: An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C 125 mL/hr of lactated ringers
Description: The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
Study: NCT03066492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Northwestern Follow Up Care Coordination
Description: Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Federally Qualified Health Center
Description: Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
Study: NCT01828463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: doses 1, 2, 4 \& 8 mg plus no treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: doses 1, 2, 4 \& 8 mg plus no treatment arm
Study: NCT05373420

Intervention type: OTHER
Intervention: Migration background
Description: Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.

Intervention type: OTHER
Intervention: Household type
Description: Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.

Intervention type: OTHER
Intervention: Health literacy
Description: Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
Study: NCT02007876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility and Activity Training
Description: Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2.
Study: NCT00893087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering mode of the ventilator
Description: 10 min of each triggering mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering mode of the ventilator
Description: 10 min of each triggering mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering mode of the ventilator
Description: 10 min of each triggering mode
Study: NCT02443311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Description: Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
Study: NCT00893087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: Flow triggering

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: Pressure triggering

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triggering method of the ventilator
Description: NAVA triggering
Study: NCT00982488

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Dasatinib was supplied as 20- and 50-mg tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Dasatinib was supplied as 20- and 50-mg tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Dasatinib was supplied as 20- and 50-mg tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Dasatinib was supplied as 20- and 50-mg tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Imatinib was supplied as 100- and 400-mg tablets.
Study: NCT00320099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50 mg as iv bolus every 6 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludrocortisone
Description: 50 µg once a day via a nasogastric tube for seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludrocortisone
Description: 50 µg once a day via a nasogastric tube for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: hydrocortisone 50mg q6 for 7 days
Study: NCT01148745

Intervention type: DRUG
Group type: OTHER
Intervention: ferumoxytol
Description: 510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
Study: NCT00950547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARDIOPAT
Description: Cell Saver System at bedside for ICU stay
Study: NCT02443311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Description: Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
Study: NCT00950547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Drains
Description: Chest drains as usual with no possibility to reinfuse lost blood
Study: NCT00195182

Intervention type: BEHAVIORAL
Intervention: Self affirmation and positive affect induction vs. control
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.

Intervention type: BEHAVIORAL
Intervention: Self affirmation and positive affect induction vs. control
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study: NCT00505843

Intervention type: DRUG
Group type: OTHER
Intervention: MK0657
Description: 7mg MK0657 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: 7mg MK0657 Pbo capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: levodopa
Description: levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: levodopa
Description: levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: carbidopa
Description: carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: carbidopa
Description: carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
Study: NCT02949492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (interleukin 2)
Description: Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
Study: NCT01477060

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Description: 1250 mg/ die, os

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Description: 1250 mg/ die, os

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1500 mg/die, os

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1500 mg/die, os